TRICAPITAL investee Ryboquin has been hitting the headlines after its recent acquisition of gene therapy pioneers Nanogenics. The new combined company, Nanogenics Ltd, is set to revolutionise gene therapy by pioneering the safe, efficacious and regular dosing of all forms of gene therapy.
Nanogenics is developing LipTide™, an artificial virus. Currently viruses and liposomes are used, which have limited applications, severe side-effects and expensive technical problems.
Here’s some of the press coverage:
Comments are closed.